S131 CP101, an Investigational Orally Administered Microbiome Therapeutic, Increases Intestinal Microbiome Diversity and Prevents Recurrent C. difficile Infection: Results From a Randomized, Placebo-Controlled Trial
American Journal of Gastroenterology | October 24, 2021 | Volume: 116 | Issue: 1 | Pages: S57-S57
10.14309/01.ajg.0000772996.83378.7c